Patents by Inventor Aline Zimmer

Aline Zimmer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and compositions for modulating the glycosylation profile of proteins
    Publication number: 20230022796
    Abstract: The present invention relates to cell culture media comprising 5-Thio-L-fucose and the use of 5-Thio-L-fucose for modulating the glycosylation profile of antibodies or other Fc containing proteins and thereby modulating the binding affinity of said proteins.
    Type: Application
    Filed: December 16, 2020
    Publication date: January 26, 2023
    Applicant: Merck Patent GmbH
    Inventors: Aline ZIMMER, Janike EHRET, Martina ZIMMERMANN
  • CELL CULTURE MEDIA
    Publication number: 20220411748
    Abstract: The present invention relates to cell culture media comprising N-lactoyl derivatives of one or more amino acid. The poor solubility of some amino acids in cell culture media is overcome by substituting them with an N-lactoyl derivative.
    Type: Application
    Filed: November 11, 2020
    Publication date: December 29, 2022
    Applicant: Merck Patent GmbH
    Inventors: Aline ZIMMER, Ronja SEIBEL, Corinna SCHMIDT, Gregor Franz Werner WILLE, Markus Klaus Robert FISCHER, Yannick Pierre REY
  • CELL CULTURE MEDIA COMPRISING KETO ACIDS
    Publication number: 20220204918
    Abstract: The present invention relates to cell culture media comprising alpha keto acids. The poor solubility of some amino acids like isoleucine, leucine and valine can be overcome by substituting them with the respective alpha keto acid.
    Type: Application
    Filed: April 8, 2020
    Publication date: June 30, 2022
    Applicant: MERCK PATENT GMBH
    Inventors: Aline ZIMMER, Ronja SEIBEL, Corinna SCHMIDT, Gregor Franz Werner WILLE, Markus Klaus Robert FISCHER
  • Method for reducing the trisulfide level in proteins
    Patent number: 11220668
    Abstract: The present invention relates to the use of sulfocysteine and derivatives thereof as cell culture additives to reduce the trisulfide levels in proteins produced in cell culture.
    Type: Grant
    Filed: April 25, 2017
    Date of Patent: January 11, 2022
    Assignee: Merck Patent GmbH
    Inventor: Aline Zimmer
  • METHOD FOR REDUCING THE TRISULFIDE LEVEL IN PROTEINS
    Publication number: 20200255796
    Abstract: The present invention relates to the use of sulfocysteine and derivatives thereof as cell culture additives to reduce the trisulfide levels in proteins produced in cell culture.
    Type: Application
    Filed: April 25, 2017
    Publication date: August 13, 2020
    Applicant: Merck Patent GmbH
    Inventor: Aline ZIMMER
  • Method for increasing the glutathione level in cells
    Patent number: 10626364
    Abstract: The present invention relates to the use of sulfocysteine and derivatives thereof to increase the gluthathione pool in cells.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: April 21, 2020
    Assignee: Merck Patent GmbH
    Inventor: Aline Zimmer
  • Methods for identifying dendritic cell subsets, for determining if a patient is developing a regulatory or an effector immune response, and for determining response to immunotherapy
    Patent number: 10190166
    Abstract: The present invention concerns methods for determining if a dendritic cell belongs to a tolerogenic dendritic cell subset or to an effector dendritic cell subset, and methods for determining if a patient undergoing immunotherapy, and/or who has been administered with a vaccine, is developing an immune response oriented either towards a regulatory T cell response or towards an effector T cell response, and methods of determining response to immunotherapy.
    Type: Grant
    Filed: September 5, 2012
    Date of Patent: January 29, 2019
    Assignee: STALLERGENES
    Inventors: Philippe Moingeon, Aline Zimmer, Julien Bouley, Laurent Mascarell, Emmanuel Nony
  • METHOD FOR INCREASING THE GLUTATHIONE LEVEL IN CELLS
    Publication number: 20180216061
    Abstract: The present invention relates to the use of sulfocysteine and derivatives thereof to increase the gluthathione pool in cells.
    Type: Application
    Filed: July 1, 2016
    Publication date: August 2, 2018
    Applicant: Merck Patent GmbH
    Inventor: Aline ZIMMER
  • Use of IGG1 immunoglobulins and/or ligands of the CD32 receptor for treating inflammatory diseases and incidents via the mucosa
    Patent number: 9822185
    Abstract: The present invention concerns the use of immunoglobulins of IgG1 type, and more generally of ligands of the CD32 receptor, for the treatment of inflammatory diseases and manifestations, in particular of allergies and auto-immune diseases, more particularly the treatment of allergic asthma, the immunoglobulins and ligands being administered via mucosal route, in particular via sublingual route.
    Type: Grant
    Filed: October 9, 2015
    Date of Patent: November 21, 2017
    Assignee: STALLERGENES
    Inventors: Thierry Batard, Philippe Moingeon, Laurent Mascarell, Aline Zimmer, Emmanuel Nony
  • USE OF IGG1 IMMUNOGLOBULINS AND/OR LIGANDS OF THE CD32 RECEPTOR FOR TREATING INFLAMMATORY DISEASES AND INCIDENTS VIA THE MUCOSA
    Publication number: 20160032018
    Abstract: The present invention concerns the use of immunoglobulins of IgG1 type, and more generally of ligands of the CD32 receptor, for the treatment of inflammatory diseases and manifestations, in particular of allergies and auto-immune diseases, more particularly the treatment of allergic asthma, the immunoglobulins and ligands being administered via mucosal route, in particular via sublingual route.
    Type: Application
    Filed: October 9, 2015
    Publication date: February 4, 2016
    Inventors: Thierry Batard, Philippe Moingeon, Laurent Mascarell, Aline Zimmer, Emmanuel Nony
  • Use of IgGimmunoglobulins and/or ligands of the CD32 receptor for treating inflammatory diseases and manifestations via the mucosal route
    Patent number: 9187568
    Abstract: The present invention concerns the use of immunoglobulins of IgG1 type, and more generally of ligands of the CD32 receptor, for the treatment of inflammatory diseases and manifestations, in particular of allergies and auto-immune diseases, more particularly the treatment of allergic asthma, the immunoglobulins and ligands being administered via mucosal route, in particular via sublingual route.
    Type: Grant
    Filed: May 7, 2010
    Date of Patent: November 17, 2015
    Assignee: STALLERGENES S.A.
    Inventors: Thierry Batard, Philippe Moingeon, Laurent Mascarell, Aline Zimmer, Emmanuel Nony
  • METHODS FOR IDENTIFYING DENDRITIC CELL SUBSETS, FOR DETERMINING IF A PATIENT IS DEVELOPING A REGULATORY OR AN EFFECTOR IMMUNE RESPONSE, AND FOR DETERMINING RESPONSE TO IMMUNOTHERAPY
    Publication number: 20140377761
    Abstract: The present invention concerns methods for determining if a dendritic cell belongs to a tolerogenic dendritic cell subset or to an effector dendritic cell subset, and methods for determining if a patient undergoing immunotherapy, and/or who has been administered with a vaccine, is developing an immune response oriented either towards a regulatory T cell response or towards an effector T cell response, and methods of determining response to immunotherapy.
    Type: Application
    Filed: September 5, 2012
    Publication date: December 25, 2014
    Applicant: STALLERGENES S.A.
    Inventors: Philippe Moingeon, Aline Zimmer, Julien Bouley, Laurent Mascarell, Emmanuel Nony
  • USE OF IGG1 IMMUNOGLOBULINS AND/OR LIGANDS OF THE CD32 RECEPTOR FOR TREATING INFLAMMATORY DISEASES AND MANIFESTATIONS VIA THE MUCOSAL ROUTE
    Publication number: 20120171198
    Abstract: The present invention concerns the use of immunoglobulins of IgG1 type, and more generally of ligands of the CD32 receptor, for the treatment of inflammatory diseases and manifestations, in particular of allergies and auto-immune diseases, more particularly the treatment of allergic asthma, the immunoglobulins and ligands being administered via mucosal route, in particular via sublingual route.
    Type: Application
    Filed: May 7, 2010
    Publication date: July 5, 2012
    Applicant: STALLERGENES S.A.
    Inventors: Thierry Batard, Philippe Moingeon, Laurent Mascarell, Aline Zimmer, Emmanuel Nony